Navigation Links
Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
Date:8/7/2012

related clinical trials, as compared to the same period in 2011, when three trials were being planned.  This was also offset by an increase of $1.1 million in manufacturing costs in the six months ended June 30, 2012 associated with initiating the nine-month dog inhalation toxicity study and building drug supply for the ongoing CLEAR-108 and TARGET-NTM clinical trials.

General and administrative expenses decreased to $5.2 million in the six months ended June 30, 2012 from $6.0 million for the six months ended June 30, 2011.
The $0.8 million decrease was due largely to lower finance, legal and consulting fees incurred in the six months ended June 30, 2011 related to post Transave merger matters and the March 2011 reverse stock split transaction.

Investment income decreased to $0.7 million in the six months ended June 30, 2012 from $1.0 million in the six months ended June 30, 2011. The decrease is a result of the lower overall average cash and short-term investments balance for the current quarter as compared to the quarter ended June 30, 2011.

As of June 30, 2012, Insmed had total cash, cash equivalents, short-term investments, and certificate of deposits on hand totalling $75.2 million, consisting of $73.1 million in cash and short-term investments and $2.1 million in a certificate of deposit, as compared to $78.4 million of cash on hand as of December 31, 2011.  The $3.2 million decrease in total cash was due primarily to the funding of operations, consisting primarily of research and development activities, totalling $12.9 million, which was primarily offset by the net $9.7 million of funding in June 2012 under the term loan with Hercules Technology Growth Capital.

Conference CallTo participate in today's live conference call, please dial 800-299-7089 (U.S. callers) or 617-801-9714 (international), and provide passcode 17092264.  A live webcast of the call will also be available at

SOURCE Insmed Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
2. Insmed Incorporated Provides Corporate Update
3. Organogenesis Announces Annual College Scholarship Award Winner
4. Bion Announces Approval of New Canadian Patent
5. PDL BioPharma Announces Second Quarter 2012 Financial Results
6. BioPower Operations Corporation Announces that FTZ Exchange Signs Strategic Alliance with Capacity 360, LLC and Tom Settineri
7. Accuray Announces First CyberKnife System in South America
8. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
9. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
10. AMRI Announces Second Quarter 2012 Results
11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Research and Markets  has announced ... - Global Strategic Business Report" report to their offering. ... Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The report ... , Europe , Asia-Pacific ... are provided for the period 2012 through 2020. Market data ...
(Date:8/19/2014)... 2014 XenoTech announces an exclusive ... metabolite production from bioactive small molecules. Based ... technology enables convenient and timely assessment of critical ... Vice President of Commercial Operations, Christian Darabant, “the ... risk can be measured directly by comparison with ...
(Date:8/19/2014)... 2014 CSSi, the leader in patient recruitment ... formation of the company,s Medical and Clinical Advisory Board ... Dr. William E. Gannon, Jr. to the ... The MCAB, with Dr. Gannon,s leadership, will ... and set strategic goals for the advancement and development ...
(Date:8/19/2014)... Aug. 19, 2014   Synthetic Biologics, Inc. ... novel anti-infective biologic and drug programs targeting specific ... today that its novel C. difficile ... th Interscience Conference on Antimicrobial Agents and ... D.C. Synthetic Biologics, Senior ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... LEXINGTON, Mass., March 11 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... the Cowen and Company 28th Annual Health Care Conference, ... conference is being held in,Boston, Massachusetts. The presentation will ... the Investors section of the Indevus website at, http://www.indevus.com ...
... March 11 Scott Lett, CEO of The,BioAnalytics ... make,scientific presentations at the Tucson Symposium on March ... Drug Discovery,Development and Clinical Diagnostics," will be attended ... biotechnology and,medical device industries., Dr. Lett,s invited ...
... STRASBOURG, France, March 11 Transgene,(Euronext Paris: FR0005175080) ... 2007 and outlook for 2008., "2007 was ... major,accomplishments: the signing of a partnership agreement with ... treatment of diseases caused by the,HPV virus, and ...
Cached Biology Technology:Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 3BioAnalytics Group CEO, Senior Scientist to Present at Tucson Symposium March 12-13 2Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 2Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 3Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 4Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 5Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 6Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 7Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 8Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 9Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 10Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 11Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 12
(Date:8/20/2014)... August 19, 2014 -- Bay Area Lyme Foundation, which ... simple to cure, applauds new research published in an ... Ticks and Tick-borne Diseases . The findings show ... are active throughout the year, making the threat of ... at California Department of Public Health (CDPH) Vector-borne Disease ...
(Date:8/20/2014)... spiciness that is irresistible to some, but intolerable to ... their findings to develop a new drug candidate for ... inflammation or other problems. They reported their progress on ... in ACS, Journal of Medicinal Chemistry . , ... had pegged a compound called capsaicin as the active ...
(Date:8/20/2014)... When a colony of honeybees grows to about 4,000 ... reproductive cycle: the building of a special type of ... team of experts from the Department of Neurobiology and ... what starts the reproductive cycle of honeybee colonies. The ... The Science of Nature . , Reproduction isn,t ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Worker bees 'know' when to invest in their reproductive future 2
... 2011 Qqest and M2SYS Technology, a global biometrics ... allows Qqest to offer TimeForce time and attendance customers ... technology at their PC. M2SYS, RightPunch(TM) solution ... to seamlessly interface with Qqest,s TimeForce time and attendance ...
... In communities all across the US, travelers that went to the ... their quiet lives. The voyagers in question are not astronauts. ... moon trees orbited the moon 34 times in the Apollo 14 ... the lunar module landed at Fra Mauro, Earth peeks over the ...
... Trees growing on farms will be essential to future development. ... year, the number of trees on farms is increasing. Marking ... United Nations Forum on Forests (UNFF9) in New York on ... Agroforestry Centre, highlighted the importance of mixing trees with agriculture, ...
Cached Biology News:Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 2Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 3A race against time to find Apollo 14's lost voyagers 2A race against time to find Apollo 14's lost voyagers 3A race against time to find Apollo 14's lost voyagers 4Putting trees on farms fundamental to future agricultural development 2Putting trees on farms fundamental to future agricultural development 3Putting trees on farms fundamental to future agricultural development 4
... for genome-wide microRNA expression profiling and ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive microRNA Expression Profiling Service. ... Viruses microRNA Microarray contains all known ...
... At the forefront of Agilent analytical solutions ... local area networking (LAN) allows you to ... fast and informed decision making. Just as ... all the flexibility and performance needed for ...
The novel and unique HCTplus delivers unmatched information-rich data-dependent LC/MSn data for todays challenge in proteomics and metabonomics work....
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
Biology Products: